Advertisement

Immunobiology and Immune-Based Therapies of Melanoma

  • Mariah R. Brown
  • John C. Ansel
  • Cheryl A. Armstrong
  • Human regulatory T cells (Tregs) play an important role in suppressing antitumor immune responses.

  • Melanoma-derived factors may convert dendritic cells into tolerance-inducing, antigen-presenting cells.

  • Adhesion molecules such as integrins, cadherins, and intercellular adhesion molecule 1 (ICAM-1) have been implicated in progression of melanoma.

  • Melanoma cells produce a variety of cytokines that allow tumor progression.

  • Surgery, chemotherapy, and immunotherapy (e.g., interferon-α and interleukin-2) are used in the treatment of melanoma.

  • A variety of vaccines are being studied for therapy of melanoma.

Keywords

Melanoma Cell Clin Oncol Metastatic Melanoma Melanoma Patient Newcastle Disease Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMedGoogle Scholar
  2. 2.
    Clark WH Jr, Elder DE, Guerry DT, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147–65.PubMedGoogle Scholar
  3. 3.
    Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004;54(3):131–49.PubMedGoogle Scholar
  4. 4.
    Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002;29:427–45.PubMedGoogle Scholar
  5. 5.
    Wagner SN, Schultewolter T, Wagner C, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998;78:541–50.PubMedGoogle Scholar
  6. 6.
    Armstrong CA, Ansel JC. Immunology of malignant melanoma. Photochem Photobiol 1996;63:418–20.PubMedGoogle Scholar
  7. 7.
    Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006;54:189–206; quiz 207–10.PubMedGoogle Scholar
  8. 8.
    Rodrigues LK, Klencke BJ, Vin-Christian K, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002;138:765– 70.PubMedGoogle Scholar
  9. 9.
    Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005;104:1505–11.PubMedGoogle Scholar
  10. 10.
    Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43–7.PubMedGoogle Scholar
  11. 11.
    Kawakami Y, Zakut R, Topalian SL, et al. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992;148:638–43.PubMedGoogle Scholar
  12. 12.
    Cebon J, MacGregor D, Scott A, et al. Immunotherapy of melanoma: targeting defined antigens. Australas J Dermatol 1997;38(suppl 1):S66–72.PubMedGoogle Scholar
  13. 13.
    Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyro-sinase gene. Proc Natl Acad Sci USA 1994;91: 9461–5.PubMedGoogle Scholar
  14. 14.
    Hill LL, Perussia B, McCue PA, et al. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res 1994;54:763–70.PubMedGoogle Scholar
  15. 15.
    Rouas-Freiss N, Bruel S, Menier C, et al. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer 2005;117:114–22.PubMedGoogle Scholar
  16. 16.
    Anichini A, Vegetti C, Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 2004;53:855–64.PubMedGoogle Scholar
  17. 17.
    Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol 2004;22:251–65.PubMedGoogle Scholar
  18. 18.
    Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423–49.PubMedGoogle Scholar
  19. 19.
    Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005;28:120–8.PubMedGoogle Scholar
  20. 20.
    Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169–77.PubMedGoogle Scholar
  21. 21.
    Enk AH, Jonuleit H, Saloga J, et al. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997;73:309–16.PubMedGoogle Scholar
  22. 22.
    Liu Y, Janeway CA, Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 1992;89:3845–9.PubMedGoogle Scholar
  23. 23.
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271–96.PubMedGoogle Scholar
  24. 24.
    Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993;7:187–91.PubMedGoogle Scholar
  25. 25.
    Haass NK, Smalley KS, Li L, et al. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005;18:150–9.PubMedGoogle Scholar
  26. 26.
    Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18:345–57.PubMedGoogle Scholar
  27. 27.
    Sers C, Riethmuller G, Johnson JP. MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematog-enous spread. Cancer Res 1994;54:5689–94.PubMedGoogle Scholar
  28. 28.
    Shih IM, Elder DE, Speicher D, et al. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994;54:2514–20.PubMedGoogle Scholar
  29. 29.
    Lehmann JM, Holzmann B, Breitbart EW, et al. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 1987;47:841–5.PubMedGoogle Scholar
  30. 30.
    Yang H, Wang S, Liu Z, et al. Isolation and characterization of mouse MUC18 cDNA gene, and correlation of MUC18 expression in mouse melanoma cell lines with metastatic ability. Gene 2001;265:133–45.PubMedGoogle Scholar
  31. 31.
    Brocker EB, Suter L, Bruggen J, et al. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 1985;36:29–35.PubMedGoogle Scholar
  32. 32.
    Luca M, Hunt B, Bucana CD, et al. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993;3:35–41.PubMedGoogle Scholar
  33. 33.
    Melnikova VO, Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006;19:395–405.PubMedGoogle Scholar
  34. 34.
    Armstrong C, Luger T, Ansel J. Cytokines and malignant melanoma. In: Mukhtar H, ed. Skin Cancer: Mechanisms and Human Relevance. Boca Raton, FL: CRC Press, 1995:273–80.Google Scholar
  35. 35.
    Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991;97:20–6.PubMedGoogle Scholar
  36. 36.
    Halaban R, Langdon R, Birchall N, et al. Basic fibrob-last growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988;107:1611–9.PubMedGoogle Scholar
  37. 37.
    Colombo MP, Maccalli C, Mattei S, et al. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 1992;2:181–9.PubMedGoogle Scholar
  38. 38.
    Armstrong CA, Tara DC, Hart CE, et al. Heterogeneity of cytokine production by human malignant melanoma cells. Exp Dermatol 1992;1:37–45.PubMedGoogle Scholar
  39. 39.
    Lazar-Molnar E, Hegyesi H, Toth S, et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547–54.PubMedGoogle Scholar
  40. 40.
    Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281–8.PubMedGoogle Scholar
  41. 41.
    Schadendorf D, Moller A, Algermissen B, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667–75.PubMedGoogle Scholar
  42. 42.
    Hensley C, Spitzler S, McAlpine BE, et al. In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 1998;7:335–41.PubMedGoogle Scholar
  43. 43.
    Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994;54:3242–7.PubMedGoogle Scholar
  44. 44.
    Wahl S. Regulation of tissue inflammation, repair, and fibrosis by transforming growth factor beta. In: Luger TA, Schwarz T, eds. Epidermal Growth Factors and Cytokines. New York: Marcel Dekker, 1994:241–52.Google Scholar
  45. 45.
    Pittelkow MR, Shipley GD. Serum-free culture of normal human melanocytes: growth kinetics and growth factor requirements. J Cell Physiol 1989;140:565–76.PubMedGoogle Scholar
  46. 46.
    Rodeck U, Bossler A, Graeven U, et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994;54:575–81.PubMedGoogle Scholar
  47. 47.
    Mattei S, Colombo MP, Melani C, et al. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994;56:853–7.PubMedGoogle Scholar
  48. 48.
    Sabatini M, Chavez J, Mundy GR, et al. Stimulation of tumor necrosis factor release from monocytic cells by the A375 human melanoma via granulocyte macrophage colony-stimulating factor. Cancer Res 1990;50:2673–8.PubMedGoogle Scholar
  49. 49.
    Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996;56:2191–8.PubMedGoogle Scholar
  50. 50.
    Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539–43.PubMedGoogle Scholar
  51. 51.
    Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630–7.PubMedGoogle Scholar
  52. 52.
    Dummer W, Becker JC, Schwaaf A, et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67–8.PubMedGoogle Scholar
  53. 53.
    Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991;147:528–34.PubMedGoogle Scholar
  54. 54.
    Kirkin AF, Dzhandzhugazyan K, Zeuthen J. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 1998;15:19–32.PubMedGoogle Scholar
  55. 55.
    Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177: 989–98.PubMedGoogle Scholar
  56. 56.
    Theos AC, Truschel ST, Raposo G, et al. The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res 2005;18:322–36.PubMedGoogle Scholar
  57. 57.
    Sakai C, Kawakami Y, Law LW, et al. Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 1997;7:83–95.PubMedGoogle Scholar
  58. 58.
    Zhai Y, Yang JC, Spiess P, et al. Cloning and characterization of the genes encoding the murine homo-logues of the human melanoma antigens MART1 and gp100. J Immunother 1997;20:15–25.PubMedGoogle Scholar
  59. 59.
    Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35–42.PubMedGoogle Scholar
  60. 60.
    Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91: 3515–9.PubMedGoogle Scholar
  61. 61.
    Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81–96.PubMedGoogle Scholar
  62. 62.
    Chambost H, Brasseur F, Coulie P, et al. A tumour-associated antigen expression in human haematolog-ical malignancies. Br J Haematol 1993;84:524–6.PubMedGoogle Scholar
  63. 63.
    Rimoldi D, Romero P, Carrel S. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 1993;54:527–8.PubMedGoogle Scholar
  64. 64.
    De Smet C, Lurquin C, van der Bruggen P, et al. Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 1994;39:121–9.PubMedGoogle Scholar
  65. 65.
    Brasseur F, Marchand M, Vanwijck R, et al. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52:839–41.PubMedGoogle Scholar
  66. 66.
    Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375–80.PubMedGoogle Scholar
  67. 67.
    Roeder C, Schuler-Thurner B, Berchtold S, et al. MAGE-A3 is a frequent tumor antigen of metas-tasized melanoma. Arch Dermatol Res 2005;296: 314–9.PubMedGoogle Scholar
  68. 68.
    Mukerjee S, Nasoff M, McKnight M, Glassy M. Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells. Hybridoma 1998;17:133–42.PubMedGoogle Scholar
  69. 69.
    Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985;45:2405–14.PubMedGoogle Scholar
  70. 70.
    Hamilton WB, Helling F, Lloyd KO, et al. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993;53:566–73.PubMedGoogle Scholar
  71. 71.
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–48.PubMedGoogle Scholar
  72. 72.
    Jack A, Boyes C, Aydin N, et al. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Surg Oncol 2006;15:13–24.PubMedGoogle Scholar
  73. 73.
    Morton DL, Wanek L, Nizze JA, et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg 1991;214:491–9; discussion 499–501.PubMedGoogle Scholar
  74. 74.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–9.PubMedGoogle Scholar
  75. 75.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307–17.PubMedGoogle Scholar
  76. 76.
    Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. N Engl J Med 2006;355:1370–1.PubMedGoogle Scholar
  77. 77.
    Johnson TM, Sondak VK, Bichakjian CK, et al. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2006;54: 19–27.PubMedGoogle Scholar
  78. 78.
    Houghton AN, Legha S, Bajorin DF. Chemotherapy for Metastatic Melanoma, 2nd ed. Philadelphia: 1994.Google Scholar
  79. 79.
    Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 2001;11:75–81.PubMedGoogle Scholar
  80. 80.
    Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158–66.PubMedGoogle Scholar
  81. 81.
    Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144–51.PubMedGoogle Scholar
  82. 82.
    Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995;75(2 suppl):726–34.PubMedGoogle Scholar
  83. 83.
    Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 2002;44: 81–102.PubMedGoogle Scholar
  84. 84.
    Verma S, Quirt I, McCready D, et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431–42.PubMedGoogle Scholar
  85. 85.
    Pardoll DM. Cancer vaccines. Nat Med 1998;4(5 suppl):525–31.PubMedGoogle Scholar
  86. 86.
    Perales MA, Chapman PB. Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses. Cancer Chemother Biol Response Modif 2005;22:749–60.PubMedGoogle Scholar
  87. 87.
    Rietschel P, Chapman PB. Immunotherapy of melanoma. Hematol Oncol Clin North Am 2006;20:751–66.PubMedGoogle Scholar
  88. 88.
    Atkins MB. Cytokine-based therapy and bioche-motherapy for advanced melanoma. Clin Cancer Res 2006;12:2353s–8s.PubMedGoogle Scholar
  89. 89.
    Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346–57.PubMedGoogle Scholar
  90. 90.
    Tepper RI, Pattengale PK, Leder P. Murine inter-leukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503–12.PubMedGoogle Scholar
  91. 91.
    Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarci-noma in vivo. J Exp Med 1991;173:889–97.PubMedGoogle Scholar
  92. 92.
    Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenic-ity and induces protective immunity. J Exp Med 1990;172:1217–24.PubMedGoogle Scholar
  93. 93.
    Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713–6.PubMedGoogle Scholar
  94. 94.
    Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397–403.PubMedGoogle Scholar
  95. 95.
    Armstrong CA, Murray N, Kennedy M, et al. Melanoma-derived interleukin 6 inhibits in vivo melanoma growth. J Invest Dermatol 1994;102: 278–84.PubMedGoogle Scholar
  96. 96.
    Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153–64.PubMedGoogle Scholar
  97. 97.
    Simons JW, Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol 1998;25: 661–76.PubMedGoogle Scholar
  98. 98.
    Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820–5.PubMedGoogle Scholar
  99. 99.
    Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human inter-leukin 12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409–17.PubMedGoogle Scholar
  100. 100.
    Kirkwood J, Kefford, R, Logan, T, et al. Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM). J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I 2006;24(18S):10043.Google Scholar
  101. 101.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–16.PubMedGoogle Scholar
  102. 102.
    Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(suppl 1):S11–4.PubMedGoogle Scholar
  103. 103.
    Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477–82.PubMedGoogle Scholar
  104. 104.
    Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006;126:2658–63.PubMedGoogle Scholar
  105. 105.
    Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107:2409–14.PubMedGoogle Scholar
  106. 106.
    Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.PubMedGoogle Scholar
  107. 107.
    Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 2000;18:2444–58.PubMedGoogle Scholar
  108. 108.
    Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–7.PubMedGoogle Scholar
  109. 109.
    Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366(9492):1189–96.PubMedGoogle Scholar
  110. 110.
    Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80–1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390–402.PubMedGoogle Scholar
  111. 111.
    Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:53–61.PubMedGoogle Scholar
  112. 112.
    Avigan D. Dendritic cells: development, function and potential use for cancer immunotherapy. Blood Rev 1999;13:51–64.PubMedGoogle Scholar
  113. 113.
    Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614–21.PubMedGoogle Scholar
  114. 114.
    Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006;12:2331s–6s.PubMedGoogle Scholar
  115. 115.
    de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 2000;6:1267–72.PubMedGoogle Scholar
  116. 116.
    Hoeller C, Jansen B, Heere-Ress E, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol 2001;117:371–4.PubMedGoogle Scholar
  117. 117.
    Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6:247–55.PubMedGoogle Scholar
  118. 118.
    Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSmunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23:8978–91.PubMedGoogle Scholar
  119. 119.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999;17:968–75.PubMedGoogle Scholar
  120. 120.
    Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 1997;15:2579–88.PubMedGoogle Scholar
  121. 121.
    Atkins MB, Flaherty LE, Sosman JA, et al. prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated inter-group trial (abstr 2847). Proc Am Soc Clin Oncol 2003;22.Google Scholar
  122. 122.
    Sasse A, Sasse E, Clark L, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007: CD005413.Google Scholar
  123. 123.
    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–65.PubMedGoogle Scholar
  124. 124.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734–6.PubMedGoogle Scholar
  125. 125.
    Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29:455–63.PubMedGoogle Scholar
  126. 126.
    Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106:2437–44.PubMedGoogle Scholar
  127. 127.
    Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated meta-static melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003;100:4712–7.PubMedGoogle Scholar
  128. 128.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372–7.PubMedGoogle Scholar
  129. 129.
    Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with met-astatic melanoma treated with anti-cytotoxic T-lym-phocyte antigen-4. J Clin Oncol 2005;23:6043–53.PubMedGoogle Scholar
  130. 130.
    Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593–8.PubMedGoogle Scholar
  131. 131.
    Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and anti-tumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168–73.PubMedGoogle Scholar
  132. 132.
    Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 2003;170:2161–9.PubMedGoogle Scholar
  133. 133.
    Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.PubMedGoogle Scholar
  134. 134.
    Ridolfi L, Ridolfi R, Riccobon A, et al. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 2003;26:156–62.PubMedGoogle Scholar
  135. 135.
    Darrow TL, Slingluff CL, Seigler HF. Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. Cancer 1988;62:84–91.PubMedGoogle Scholar
  136. 136.
    Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159–66.PubMedGoogle Scholar
  137. 137.
    Arienti F, Belli F, Rivoltini L, et al. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol Immunother 1993;36:315–22.PubMedGoogle Scholar
  138. 138.
    Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 1984;3:491–500.PubMedGoogle Scholar
  139. 139.
    Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125–30.PubMedGoogle Scholar
  140. 140.
    Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immuno-therapy-how far can we go? Nat Clin Pract Oncol 2006;3:668–81.PubMedGoogle Scholar
  141. 141.
    McIllmurray MB, Embleton MJ, Reeves WG,et al. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J 1977;1:540–2.PubMedGoogle Scholar
  142. 142.
    McIllmurray MB, Reeves WG, Langman MJ, et al. Active immunotherapy in malignant melanoma. Br Med J 1978;1:579.PubMedGoogle Scholar
  143. 143.
    Aranha GV, McKhann CF, Grage TB, et al. Adjuvant immunotherapy of malignant melanoma. Cancer 1979;43:1297–303.PubMedGoogle Scholar
  144. 144.
    Berd D, Sato T, Cohn H, et al. Treatment of meta-static melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metas-tases. Int J Cancer 2001;94:531–9.PubMedGoogle Scholar
  145. 145.
    Berd D, Sato T, Maguire HC Jr, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403–15.PubMedGoogle Scholar
  146. 146.
    Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002;20:4169–80.PubMedGoogle Scholar
  147. 147.
    Lee KP, Raez LE, Podack ER. Heat shock protein-based cancer vaccines. Hematol Oncol Clin North Am 2006;20:637–59.PubMedGoogle Scholar
  148. 148.
    Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343–50.PubMedGoogle Scholar
  149. 149.
    Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141–6.PubMedGoogle Scholar
  150. 150.
    Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882–7.PubMedGoogle Scholar
  151. 151.
    Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623–35.PubMedGoogle Scholar
  152. 152.
    Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058–66.PubMedGoogle Scholar
  153. 153.
    Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20:2067–75.PubMedGoogle Scholar
  154. 154.
    Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs 2005;19:247–60.PubMedGoogle Scholar
  155. 155.
    Sinkovics J, Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology 1993;36:193–214.PubMedGoogle Scholar
  156. 156.
    Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitu-tional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34–42.PubMedGoogle Scholar
  157. 157.
    Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69–77.PubMedGoogle Scholar
  158. 158.
    Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983;52:856–60.PubMedGoogle Scholar
  159. 159.
    Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated post-surgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992;9:169–71.PubMedGoogle Scholar
  160. 160.
    Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 1998;4:783–94.PubMedGoogle Scholar
  161. 161.
    von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of inter-feron-alpha/beta. Cell Immunol 1990;126:80–90.Google Scholar
  162. 162.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321–7.PubMedGoogle Scholar
  163. 163.
    Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with meta-static melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219–30.PubMedGoogle Scholar
  164. 164.
    Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37–44.PubMedGoogle Scholar
  165. 165.
    Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000;23:275–81.PubMedGoogle Scholar
  166. 166.
    Talebi T, Weber JS. Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 2003;13:431–8.PubMedGoogle Scholar
  167. 167.
    Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036–44.PubMedGoogle Scholar
  168. 168.
    Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2- keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res 2000;6:874–9.PubMedGoogle Scholar
  169. 169.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/ QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J Clin Oncol 2001;19:2370–80.PubMedGoogle Scholar
  170. 170.
    Ragupathi G, Meyers M, Adluri S, et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 2000;85:659–66.PubMedGoogle Scholar
  171. 171.
    Chapman PB. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Invest Drugs 2003;4:710–5.Google Scholar
  172. 172.
    Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376–84.PubMedGoogle Scholar
  173. 173.
    Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168:2523–9.PubMedGoogle Scholar
  174. 174.
    Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic cell-based vaccination against cancer. Hematol Oncol Clin North Am 2006;20:689–710.PubMedGoogle Scholar
  175. 175.
    Campton K, Ding W, Yan Z, et al. Tumor antigen presentation by dermal antigen-presenting cells. J Invest Dermatol 2000;115:57–61.PubMedGoogle Scholar
  176. 176.
    Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000;191:1699–708.PubMedGoogle Scholar
  177. 177.
    Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.PubMedGoogle Scholar
  178. 178.
    Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279–88.PubMedGoogle Scholar
  179. 179.
    Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451–8.PubMedGoogle Scholar
  180. 180.
    O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387–95.PubMedGoogle Scholar
  181. 181.
    Chang AE, Redman BG Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021–32.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Mariah R. Brown
    • 1
  • John C. Ansel
    • 1
  • Cheryl A. Armstrong
    • 1
  1. 1.Department of DermatologyUniversity of Colorado at Denver and Health Sciences CenterAuroraUSA

Personalised recommendations